Basel Medical Group Ltd shares rise 3.63% premarket after Idorsia's collaboration with Stanford and Duke for hypertension management.

Basel Medical Group Ltd rose 3.63% in premarket trading, with the company's stock price increase potentially influenced by the recent collaboration between Idorsia and two leading academic medical centers to launch a new program aimed at improving outcomes for hypertension patients. This initiative, led by Dr. Vivek Bhalla of Stanford University and Dr. Sreekanth Vemulapalli of Duke University, focuses on standardizing treatment, generating real-world evidence, and exploring AI-powered tools to enhance patient care.